Activity Prediction and Structural Insights of Extracellular Signal‐Regulated Kinase 2 Inhibitors with Molecular Dynamics Simulations
暂无分享,去创建一个
Giulio Rastelli | Alberto Del Rio | Benedetta Frida Baldi | G. Rastelli | A. Del Rio | B. Baldi | Benedetta Frida Baldi
[1] J Downward,et al. Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. , 1994, The Journal of biological chemistry.
[2] E. Goldsmith,et al. Mutation of position 52 in ERK2 creates a nonproductive binding mode for adenosine 5'-triphosphate. , 1996, Biochemistry.
[3] E. Goldsmith,et al. Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.
[4] P. Kollman,et al. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.
[5] A. Bridges,et al. Chemical inhibitors of protein kinases. , 2001, Chemical reviews.
[6] L. Johnson,et al. Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.
[7] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[8] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[9] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[10] Ken Garber,et al. The second wave in kinase cancer drugs , 2006, Nature Biotechnology.
[11] U. Ryde,et al. Ligand affinities predicted with the MM/PBSA method: dependence on the simulation method and the force field. , 2006, Journal of Medicinal Chemistry.
[12] Paul D Lyne,et al. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.
[13] A. Ferrari,et al. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. , 2007, Bioorganic & medicinal chemistry.
[14] Xiaoling Xie,et al. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. , 2007, Journal of medicinal chemistry.
[15] L. Amzel,et al. Compensating Enthalpic and Entropic Changes Hinder Binding Affinity Optimization , 2007, Chemical biology & drug design.
[16] M. Gilson,et al. Calculation of protein-ligand binding affinities. , 2007, Annual review of biophysics and biomolecular structure.
[17] Are MAP Kinases Drug Targets? Yes, but Difficult Ones , 2007, ChemMedChem.
[18] S. Knapp,et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.
[19] Steven W. Muchmore,et al. Rapid Estimation of Relative Protein-Ligand Binding Affinities Using a High-Throughput Version of MM-PBSA , 2007, J. Chem. Inf. Model..
[20] W. El-Deiry,et al. ERK and MDM2 prey on FOXO3a , 2008, Nature Cell Biology.
[21] J. Zou,et al. Effect of mutation K85R on GSK-3beta: Molecular dynamics simulation. , 2008, Biochemical and biophysical research communications.
[22] Giulio Rastelli,et al. Molecular modeling and crystal structure of ERK2-hypothemycin complexes. , 2008, Journal of structural biology.
[23] G. Degliesposti,et al. Binding Estimation after Refinement, a New Automated Procedure for the Refinement and Rescoring of Docked Ligands in Virtual Screening , 2009, Chemical biology & drug design.
[24] Allan Wissner,et al. Kinase domain mutations in cancer: implications for small molecule drug design strategies. , 2009, Journal of medicinal chemistry.
[25] Giulio Rastelli,et al. Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..